TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

Theravance Biopharma

Status and phase: Completed; Phase 1

Conditions: Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

Treatments: Drug: Nezulcitinib (TD-0903) Dose A; Drug: Nezulcitinib (TD-0903) Dose B

Study type: Interventional

Funder types: Industry

Identifiers

NCT05091723

0196

Details and patient eligibility

About

This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation.

Full description

A Phase 1, open-label, fixed-sequence, 4-period study to evaluate the plasma PK, safety and tolerability of single inhaled doses of nezulcitinib (TD-0903) administered under different supplemental oxygenation scenarios in healthy participants.

Approximately 14 healthy adult male and female participants will receive a single inhaled dose of nezulcitinib using a nebulizer device on Day 1 of each administration period, under different supplementary oxygenations conditions.

Administration A: Dose A nezulcitinib delivered by nasal inhalation via the Aerogen Solo with a high-flow nasal cannula circuit delivering supplemental oxygen, Administration B: Dose A nezulcitinib delivered by oral inhalation via the Aerogen Solo together with the Aerogen Ultra handheld device with a low-flow nasal cannula delivering supplemental oxygen, Administration C: Dose A nezulcitinib delivered by oral inhalation via the Aerogen Solo together with the Aerogen Ultra handheld device with a high-flow nasal cannula delivering supplemental oxygen, Administration D: Nezulcitinib delivered by inhalation. Route to be determined based on data from administration A-C.

Enrollment: 14 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body mass index (BMI) ≥ 18.0 and ≤ 35.0 kg/m2 and weighs at least 50 kg at screening
• Medically healthy with no clinically significant medical history, physical examination, spirometry, laboratory profiles, vital signs or ECGs
• Forced expiratory volume of 1 second (FEV1) ≥80% predicted at screening and prior to dosing
• No clinically significant abnormalities in the results of laboratory
• Female subjects must be either of non-childbearing potential or if of childbearing potential, subject must not be pregnant or breastfeeding, and must agree to use a highly effective birth control method
• Male subjects must agree to use condoms to prevent potential fetal or partner exposure through seminal fluid, in addition to the use of highly effective pregnancy prevention measures with female partners of childbearing potential
• Able to understand the correct technique for the use of the nebulizer device
• Other inclusion criteria apply

Exclusion criteria

• History or presence of clinically significant medical or psychiatric condition
• Abnormal ECG measurements at screening
• Any signs of respiratory tract infection within 6 weeks of screening
• Has a current bacterial, parasitic, fungal, or viral infection; any infection requiring hospitalization or intravenous antibiotics within 6 months prior to screening
• Has any condition of the oro-laryngeal or respiratory tract
• History or presence of alcoholism or drug abuse
• Positive urine drugs of abuse test
• Positive urine or breath alcohol results
• Uses or has used tobacco or nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, patches etc.) within 6 months prior to screening
• Tests positive for active COVID-19
• Additional exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

14 participants in 4 patient groups

Administration Scenario A

Experimental group

Description:

Single dose of TD-0903 at Dose A on Day 1, Period 1 delivered by nasal inhalation via nebulizer device with a high-flow nasal cannula delivering supplemental oxygen

Treatment:

Drug: Nezulcitinib (TD-0903) Dose A

Administration Scenario B

Experimental group

Description:

Single dose of TD-0903 at Dose A on Day 1, Period 2 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via low-flow nasal cannula

Treatment:

Drug: Nezulcitinib (TD-0903) Dose A

Administration Scenario C

Experimental group

Description:

Single dose of TD-0903 at Dose A on Day 1, Period 3 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via high-flow nasal cannula

Treatment:

Drug: Nezulcitinib (TD-0903) Dose A

Administration Scenario D

Experimental group

Description:

Single dose of TD-0903 at Dose B on Day 1, Period 4 delivered by a route to-be-determined based on data from Scenarios A, B and C.

Treatment:

Drug: Nezulcitinib (TD-0903) Dose B